IMR Press / FBL / Volume 14 / Issue 4 / DOI: 10.2741/3304

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

SUMO conjugation and cardiovascular development
Show Less
1 Institute of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe, Boulevard, Houston, TX 77030
Front. Biosci. (Landmark Ed) 2009, 14(4), 1219–1229;
Published: 1 January 2009

SUMOs (Small Ubiquitin-like modifiers) belong to a superfamily of ubiquitin like proteins (Ubls) that are covalently conjugated to their substrates via enzymatic cascade reactions. The heterodimeric activating complex (SAE1/SAE2, E1) and conjugating enzyme (Ubc9, E2) required for the SUMO conjugation pathway are distinct from those involved in other Ubl pathways, and the presence of ligases (E3) stimulates the conjugation reaction. SUMO is implicated in a variety of physiological as well as pathological processes such as cell division, signal transduction, DNA damage and repair, and cancer development. This review focuses on the fundamental features of SUMO conjugation and its potential implication in cardiovascular development.

Back to top